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OBJECTIVE — We investigated the relationship between maternal circulating fatty acids
(FAs) and dietary FA intake in pregnant women with gestational diabetes mellitus (GDM; n 
49), women with hyperglycemia less severe than GDM (impaired glucose challenge test [GCT]
non-GDM; n  80), and normal control subjects (n  98).
RESEARCH DESIGN AND METHODS — A case-control design was nested within a
prospective cohort of healthy pregnant women. Fasting concentrations of serum total FAs (en-
zymatic assay) and FA composition (gas chromatography–mass spectrometry) were determined
at entry and the third trimester. Dietary fat intake data were obtained from 24-h recalls.
RESULTS — There was a graded increase among groups (control subjects, impaired GCT
non-GDM, and GDM) during the third trimester for total FAs and individual FAs, including
myristic, palmitic, palmitoleic, oleic, linoleic, linolenic, arachidonic, eicosapentaenoic, and do-
cosahexaenoic acids (P for trend 0.03 to P  0.001). Similar relationships were observed at
entry in total FAs and for four FAs (myristic, palmitic, palmitoleic, and eicosapentaenoic acids).
Women with impaired GCT non-GDM with BMI 25 kg/m
2 had the highest levels of FAs at
entry, whereas women with GDM with BMI 25 kg/m
2 had the highest levels during the third
trimester, and all grouped FAs were signiﬁcantly different from lean women with impaired GCT
non-GDM or control subjects (P  0.05). Dietary intake of polyunsaturated FAs was decreased,
but saturated FAs were increased in GDM compared with impaired GCT non-GDM or control
subjects (P  0.05).
CONCLUSIONS — Abnormalities in fat metabolism are present in both GDM and impaired
GCT non-GDM women. Reducing pregravid weight and altering diet might prevent the associ-
ated elevation of circulating FAs.
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M
any studies suggested that mater-
nal circulating fatty acids (FAs)
play important roles in fetal
growth and development (1–2). How-
ever, elevated maternal circulating total
FAs are associated with increased insulin
resistance and -cell dysfunction, which
contribute to the development of gesta-
tional diabetes mellitus (GDM) and in-
crease risk of adverse perinatal outcomes,
includingpretermdelivery(3–4).Lessat-
tention has been focused on the relation-
ship between FA composition and GDM.
Published data (5–6) are inconclusive on
which individual FAs are altered in GDM
and the importance of these changes, if
any. Dietary saturated fat intake is associ-
atedwithincreasedriskoftype2diabetes
and increased polyunsaturated fat intake
with a reduced risk (7). Similar results have
been found in some, but not all, studies
with GDM, with the difference in results
probably being due to the effect of dietary
counseling after GDM diagnosis (8–9).
Recentstudieshavereportedthatma-
ternal glucose intolerance less severe than
overtGDMisassociatedwithanincreased
risk of adverse pregnancy outcomes (10).
These observations raise important ques-
tions because 9–19% of pregnant
women have hyperglycemia during fast-
ing or an oral glucose load but do not
meetthediagnosticcriteriaforGDM(11).
These patients generally are not provided
the usual diabetes care. Consequently,
thereislittleinformationonwhethermet-
abolic abnormalities in FA composition
exist in these women and if their dietary
fat intake differs from women with meta-
bolically normal pregnancies.
Therefore, we used a nested case-
control design to investigate whether ele-
vated concentrations of serum FA and
alerted FA composition were present not
only in women with overt GDM but also
in those with less severe glucose intoler-
ance. In addition, we examined whether
the corresponding dietary FA intake dif-
fered among groups and correlated with
serum FA concentration.
RESEARCH DESIGN AND
METHODS— We conducted a case-
control study nested within the Camden
Study (12), a prospective cohort study of
pregnancy outcome and complications in
young, generally healthy women residing
in one of the poorest cities in the conti-
nentalU.S.Theinstitutionalreviewboard
at the University of Medicine and Den-
tistry of New Jersey, School of Osteo-
pathic Medicine, approved the study
protocol. Informed written consent was
obtained from each participant after ex-
planationofthenatureandpurposeofthe
study.
Data regarding socioeconomic status,
demographics, and lifestyle were ob-
tained by interview at entry to care (15
weeksofgestation)andupdatedat20and
28 weeks of gestation. Ethnicity was self-
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self-reported pregravid weight and mea-
sured height at entry to prenatal care (kg/
m
2). Maternal obesity was deﬁned as BMI
30 kg/m
2 (13). Fasting blood samples
(8 h) were obtained to measure serum
FAconcentrationsandcompositionaten-
try to care (16.5  0.16 weeks) and dur-
ing the third trimester (30.76  0.16
weeks) (means  SE). Serum samples
were centrifuged at 4°C and stored at
70°C for assay. After exclusions of
women who had serious nonobstetric
problems, the cohort of 2,379 partici-
pants enrolled between 1996 and 2006
were used to select case and control
subjects.
Case subject deﬁnition
Cases of GDM were selected from among
participants with a positive glucose chal-
lenge test (GCT) at 28 weeks’ gestation
(27.7  0.2 weeks) (means  SE) (1-h
plasma glucose concentration 140
mg/dl after a 50-g oral glucose load) and
with two or more glucose values over the
cutpointsof95,180,155,and140mg/dl
at fasting, 1, 2, and 3 h during a 100-g
diagnostic oral glucose tolerance test
(OGTT) (the Carpenter/Coustan conver-
sion recommended by the American Dia-
betes Association) (14). All patients
diagnosed with GDM (4.2% of the co-
hort)weretreatedwithdietarycounseling
and/or insulin. Women with a positive
GCT and fewer than two abnormal glu-
cose values during an OGTT were identi-
ﬁed as cases of impaired GCT non-GDM
(7.1%ofthecohort).GravidaewithGDM
(n  49), impaired GCT non-GDM (n 
80), and normal GCT (glucose 140
mg/dl at GCT) (n  98) were randomly
selected from the cohort to yield two con-
trol subjects per case subject of GDM and
aboutonecontrolsubjectpercasesubject
of impaired CGT non-GDM (SAS Proce-
dure, PROC SURVEYSELECT). The sam-
ple size is sufﬁcient to detect a very small
effect (0.05 SD units, equivalent to a cor-
relation coefﬁcient of r  0.1), with a
power of 85% (one-way ANOVA for
groups of unequal size at 5% and
two-sided test).
Analytic procedures
We measured the concentration and rela-
tive abundance of myristic, palmitic,
stearic, palmitoleic, oleic, linoleic, linole-
nic, arachidonic, eicosapentenoic (EPA),
and docosahexenoic (DHA) FAs. Total
lipids were extracted by a modiﬁed Folch
method and analyzed by gas chromatog-
raphy/mass spectrometry (GCMS) (5973
MS/6890 GC; Agilent Technologies,
Santa Clara, CA) (15). Brieﬂy, serum lip-
ids were extracted by adding 5 ml of a
mixture of 1 N HCl:heptane:propan-2-ol
(1:10:40). The extracted lipids were dis-
solved in chloroform and separated by
thin-layer chromatography. The FA band
was cut out and FA methyl esters were
prepared by esteriﬁcation with 1 ml of
14% BF3/CH3OH. The resultant esters
were redissolved in hexane and separated
by GCMS using a fused-silica capillary
column (Rtx-20; Restek, Bellefonte, PA).
Peak retention times were identiﬁed by
injecting known standards (Sigma-
Aldrich, St. Louis, MO).
ThepeakareaofFAswasidentiﬁedas
percentage of total area under the peaks,
and absolute concentration of FAs was
quantiﬁedbymultiplyingeachindividual
FA in relative value (%) by the total FA
concentration (	mol/l) determined by an
enzymatic assay kit (Wako Chemicals,
Richmond, VA). Total saturated FAs
(SFAs)(thesumofmyristic,palmitic,and
stearic acids), total monounsaturated FAs
(MUFAs) (the sum of palmitoleic and
oleic acids), and total polyunsaturated
FAs (PUFAs) (the sum of linoleic, linole-
nic, arachidonic, EPA, and DHA) were
computed.
Dietary data
A 24-h recall of the previous day’s diet
was obtained at entry to care and weeks
20 and 28 of gestation and were pro-
cessed with databases from the Campbell
Institute of Research and Technology
(CampbellSoupCompany)inCamdenas
described previously (16). The database
generates data for 70 nutrients and 19
FAsusingtheU.S.DepartmentofAgricul-
ture Nutrient Database for Standard
Reference (http://www.nal.usda.gov/fnic/
foodcomp) and the Continuing Survey of
Food Intakes by Individuals. The mean of
three 24-h recalls was used to calculate
the total daily intake of energy, fat, carbo-
hydrate, protein, individual FAs, SFAs,
MUFAs, and PUFAs, accordingly.
Statistical analysis
Univariate statistics were calculated for
continuous variables, and 

2 test was
used for categorical variables. ANOVA
was used to assess the signiﬁcance of the
linear trends among groups with various
degrees of hyperglycemia and the normal
control subjects; pairwise contrasts were
computed to compare case with control
subjects. Data on dietary FA intake were
adjusted for total fat and energy intake. A
stratiﬁed analysis by maternal overweight
and obesity (BMI 25 vs. BMI 25 kg/
m
2) was performed to test if the
differences in FA composition and hyper-
glycemia were independent of maternal
adiposity. Potential confounding vari-
ables including maternal age, ethnicity,
parity, and cigarette smoking were con-
trolled in multivariable models. All statis-
tical analyses were performed using SAS
version 9.1 (SAS Institute, Cary, NC).
RESULTS— Maternal characteristics
are shown in Table 1. As expected, pa-
tients with GDM or impaired GCT non-
GDM were older and had higher
pregravid BMI (P for trend 0.001). In
Table 1—Characteristics of participants
GDM
Impaired GCT
non-GDM Normal GCT
P for
trend
n 49 80 98
Age (years) 25.63  0.81 24.48  0.65 21.29  0.54 0.001
BMI (kg/m
2) 30.76  0.93 26.93  0.71 25.40  0.56 0.001
Obese (BMI 30 kg/m
2) 22 (44.9) 21 (26.3) 18 (18.4) 0.01
Parimipara 15 (30.6) 26 (32.5) 46 (46.9) 0.065
Ethnicity
Hispanic 30 (61.2) 38 (47.5) 35 (35.7)
African American 6 (12.2) 31 (38.8) 49 (50.0)
Caucasian and other 13 (26.5) 11 (13.8) 14 (14.3) 0.001
Cigarette smoking 15 (30.6) 23 (28.8) 19 (19.4) 0.21
Medicaid 49 (100) 80 (100) 96 (98.0) 0.26
Gestational age at delivery* 38.09  0.29 38.68  0.22 38.90  0.20 0.033
Infant birth weight (g)† 3,325  67 3,210  50 3,152  47 0.047
Data are means  SE or n (%). *Adjusted for maternal age, BMI, and cigarette smoking. †Adjusted for
maternal age, BMI, gestational age at delivery, and cigarette smoking.
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fewer African American women in the
GDM group (P  0.001). The mean ges-
tational age at delivery was signiﬁcantly
shorterandinfantbirthweightwassignif-
icantly greater in the GDM group than in
the control group (P  0.05 for each).
Serum FA composition
Maternal serum FA composition in abso-
luteconcentrationandexpressedasaper-
cent of total FAs are given in Table 2,
which compares FAs concentrations and
distributionpatternsforthethreegroups:
control subjects, impaired GCT non-
GDM, and GDM. We found a graded re-
lationship between the severity of
maternal hyperglycemia and concentra-
tions of individual FAs at both entry and
the third trimester (e.g., women with
GDMhadthehighestandcontrolsubjects
had the lowest FA concentration; the FA
concentrationwasintermediateintheim-
paired GCT non-GDM group). During
the third trimester, the absolute concen-
tration of all individual FAs (except
stearic acid) and the sum of SFAs, MU-
FAs,andPUFAsshowedsigniﬁcantlinear
trends (	mol/l, means  SE). The differ-
ences between the GDM and the control
subjects were all signiﬁcant (P  0.05 for
each). Only two differences were found
between the GDM and impaired GCT
non-GDM groups, the concentrations of
palmitoleic acid and DHA.
At entry to care, the trends were less
pronounced. Signiﬁcance was only found
with a few FAs (myristic acid, palmitic
acid, palmitoleic acid, EPAs, SFAs, and
total FAs) for GDM versus control sub-
jects(P0.05toP0.01).Additionally,
palmitic acids and total SFAs were signif-
icantly higher in the impaired GCT non-
GDM group than in control subjects
(Table 2).
In contrast, the relationship between
severity of maternal hyperglycemia and
FA composition when expressed in rela-
tive values (percentage of total FAs) was
notconsistent.Duringthethirdtrimester,
womenwithGDMhadalowerpercentage
of stearic acid and SFAs but a higher per-
centageofpalmitoleicacid,oleicacid,and
MUFAsthanincontrolsubjects(P0.05
for each) (Table 2). Similar results were
found at entry for stearic and palmitoleic
acids (P  0.05 for each). Other FAs did
not show differences between groups.
Serum FAs, hyperglycemia, and BMI
We further examined the differences of
serum FAs and hyperglycemia with and
without overweight or obesity after ad-
justing for maternal covariates (Table 3).
At entry, impaired GCT non-GDM
women with BMI 25 kg/m
2 had the
highest concentrations of FAs among
three groups. The differences were signif-
icant compared with lean women with
impaired GCT non-GDM (P  0.05 to
P  0.01 for each), and similar results
wereobservedincomparisontoleancon-
trol subjects (P  0.01 for each).
During the third trimester, GDM
women with BMI 25 kg/m
2 had the
highest concentrations of FAs among the
groups, having SFAs, MUFAs, PUFAs,
andtotalFAsthatwerehigherthaninlean
control women (P  0.01 for each), and
SFAs, PUFAs, and total FAs were also
higher than in lean women with impaired
GCT non-GDM. In addition, control sub-
jects with BMI 25 kg/m
2 had higher
MUFAs and PUFAs than in lean control
women (P  0.05 for each) (Table 3).
Dietary fat and FA intake
The mean of dietary fat and correspond-
ing FA intake for the three groups are
shown in Table 4. The intake of FAs was
adjusted for total energy and total fat in-
take. The total fat intake, expressed as
grams per day (adjusted for energy in-
take) or as the percentage of energy, did
not differ signiﬁcantly among groups.
There were signiﬁcant trends for PUFA
(P  0.01), linoleic acid (P  0.01), and
DHA(P0.05)intaketobehigherinthe
normal control subjects, whereas women
with GDM had higher intakes of total
SFAs(P0.05),palmiticacid(P0.01),
and stearic acid (P  0.05) than either
impaired GCT non-GDM and/or control
subjects.
Correlations between serum FAs and
dietary FA intake
We correlated serum individual FAs and
groupedFAs(SFAs,MUFAs,PUFAs)(asa
percentage of serum total FAs) with the
correspondingdietaryFAintake(asaper-
centage of total fat intake) adjusted for
energy intake. A positive correlation was
only observed between serum PUFAs
withdietaryPUFAintake(r0.222,P
0.05 for GDM, r  0.247, P  0.05 for
impaired GCT non-GDM and r  0.279,
P  0.01 for control subjects). The corre-
lations on other FAs were nonsigniﬁcant
and negligible.
CONCLUSIONS— Ourresultsshow
that the concentration of total FA, many
individual FAs, and grouped FAs (SFAs,
MUFAs,PUFAs)wereelevatednotonlyin
women with GDM but also in women
with impaired GCT non-GDM when
compared with control subjects. There
were also group-related differences in di-
etary intake. Maternal pregravid over-
weight or obesity (BMI 25 kg/m
2)
appears a signiﬁcant contributor to an in-
creasedlevelofserumFAs.Toourknowl-
edge, ours is the ﬁrst study of maternal
serum FA composition in impaired GCT
non-GDM subjects in young minority
women from the U.S.
A growing body of evidence supports
the concept that women with maternal
hyperglycemia less severe than the overt
GDM are also at an increased risk of ad-
verse perinatal outcomes (10). Treatment
for mild hyperglycemia reduces the asso-
ciated risk (17). Chronic elevation in cir-
culating FAs have been linked to
increased insulin resistance and inﬂam-
mation, which are associated with risk of
type 2 diabetes and cardiovascular dis-
eases (18–19). Increased maternal circu-
lating FAs were found to be a signiﬁcant
pathogenic factor for GDM, preeclamp-
sia,andriskofpretermdelivery(3–4,20).
However, little is known about whether
FA concentrations are also elevated in
women with mild or moderate hypergly-
cemiaorifFAcompositionand/ordietary
FA intake are altered in such cases. Our
data showed a graded trend between the
severity of maternal hyperglycemia and
serumFAcomposition.Actualconcentra-
tions in 9 of 10 FAs and all grouped FAs
(SFAs, MUFAs, and PUFAs) were signiﬁ-
cantly elevated in GDM women during
the third trimester. Likewise several ma-
jor SFAs were elevated at entry when
compared with normal control subjects.
The concentrations of individual FAs
and grouped FAs in women with im-
paired GCT non-GDM were moderately
elevated and, for the most part, differed
littlefromconcentrationsingravidaewith
GDM. When compared against the con-
trol subjects, SFA (palmitate acid, total
SFAs at entry, and myristic acid at the
third trimester) levels were signiﬁcantly
higher (Tables 2). In contrast, prior stud-
ies showed no major differences in the
individual FAs, including PUFAs (per-
centage of total FAs) between GDM and
control subjects (5).
Obesity is an important pathogenic
factor for diabetes and cardiovascual dis-
ease (18). In nonpregnant overweight or
obese subjects, the total FA levels are
commonly elevated, but FA composition,
expressed as a percentage of total FAs,
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jects (19). We found that at entry to care,
overweight or obese women with im-
paired GCT non-GDM had signiﬁcantly
higher concentrations of SFAs, MUFAs,
PUFAs, and total FAs as compared with
lean impaired GCT non-GDM and lean
control subjects, whereas GDM women
with BMI 25 kg/m
2 had the highest FAs
during the third trimester. These data
suggest that in addition to a mild hyper-
glycemia, gravidae with impaired GCT
non-GDM, especially in those who are
overweight or obese, have abnormalities
in fat metabolism. It is likely that, in these
women,increasedinsulinresistancegives
rise to a reduction in insulin suppression
of lipolysis as it does in GDM (3,21).
Dietary fat intake, especially the es-
sential FAs, which cannot be synthesized
by humans, are particularly important in
pregnancy, because the essential FAs re-
quired by the fetus must come from the
mother across the placenta (1). They play
critical roles in the development of fetal
membrane structures and oxidative sub-
stances (2). Data on relation of dietary fat
or FA intake to GDM remain controver-
sial. Early gestational intakes of total fat,
SFAs and PUFAs do not seem to be asso-
ciated with risk of GDM (22). Data sug-
gest that intake of SFAs or PUFAs was
decreased or that there was no difference
during the third trimester between GDM
women and control subjects (8–9). We
used the mean of three 24-h recalls to
evaluate dietary nutrient intake and
found a signiﬁcant graded trend in total
PUFAs, linoleic acid, and DHA intake,
which was the lowest in the GDM group
and highest in the control subjects, with
the impaired GCT non-GDM group fall-
ing in the middle (P  0.05 for all) (Table
4). The reverse was observed with SFA,
palmitic acid, and stearic acid intake, in
agreement with a prior report (23).
Sunetal.(24)observedamoderateto
strongcorrelationbetweenn-3FAsofma-
rine origin in erythrocytes and corre-
sponding dietary intake. Others reported
correlationsbetweendietaryintakeoflin-
olenic and linoleic acids and plasma con-
centrations in fasting whole blood,
plasma, or adipose tissue (25). We found
a moderate correlation between some of
the essential fatty acids—serum total
PUFAs and dietary PUFAs—in each group
(P  0.05) but did not ﬁnd signiﬁcant
correlations with other FAs. It is known
that SFAs and MUFAs can be synthesized
endogenously, thus correlations between
tissue levels and diet would not be antic-
ipated (9,24–25). In addition, the distri-
bution of FAs (including PUFAs) could
vary substantially in tissues because of
metabolic changes and different physio-
logic roles of FAs (25). Larger samples
size may be required to detect small to
Table 3—Serum FAs (mol/l) in three groups stratiﬁed by overweight or obesity*
BMI 25 kg/m
2 BMI 25 kg/m
2
GDM
Impaired GCT
non-GDM Control subjects GDM
Impaired GCT
non-GDM Control subjects
n 10 36 53 39 44 45
Entry
SFAs 227.02  16.27 244.13  15.32 206.65  14.83 243.50  32.62 196.37  16.60† 184.91  14.47‡
MUFAs 116.07  14.36 133.66  13.52 108.79  13.91 105.37  28.78 73.92  14.65‡§ 73.41  12.78‡§
PUFAs 58.09  6.66 66.87  6.27 56.17  6.07 59.78  13.35 40.37  6.79‡ 42.17  5.92‡
Total free FAs 401.85  34.15 444.83  32.16 371.59  31.15 407.53  68.51 306.86  34.43‡ 299.86  30.41‡§
Third trimester
SFAs 235.71  16.80 197.31  14.60 189.90  14.21 198.02  28.56 200.34  15.21§ 169.29  13.33 
MUFAs 149.80  14.30 118.81  12.42 113.78  12.10 85.40  24.31 102.61  12.92† 75.90  11.34‡ ¶
PUFAs 69.47  6.31 56.07  5.48 55.98  5.33 45.80  10.72 49.84  5.7§ 39.95  5.00† ¶
Total free FAs 455.10  35.00 372.28  30.39 359.66  29.59§ 329.41  59.47 351.74  31.1§ 285.17  27.76† 
Data are means  SE. *Models were adjusted for age, ethnicity, parity, and cigarette smoking; †P  0.05 vs. impaired GCT non-GDM with BMI 25 kg/m
2;‡ P 
0.01 vs. impaired GCT non-GDM with BMI 25 kg/m
2;§ P  0.05 vs. GDM with BMI 25 kg/m
2;  P  0.01 vs. GDM with BMI 25 kg/m
2;¶ P  0.05 vs. control
subjects with BMI 25 kg/m
2.
Table 4—Dietary fat/FA intake (g/day) by glycemic group*
GDM
Impaired GCT
non-GDM Normal GCT
P for
trend
Total fat 84.16  2.70 86.66  7.10 86.80  1.91 NS
Total fat percentage of energy 32.70  1.00 32.69  0.78 34.14  0.70 NS
Carbohydrate 294.54  8.52 288.01  6.57 287.65  5.96 NS
Protein 91.14  3.83 93.46  2.96 93.25  2.68 NS
Mysteric acid (14:0) 3.25  0.18 3.03  0.14 3.02  0.12 NS
Palmitic acid (16:0) 18.35  0.28 17.61  0.21‡ 17.36  0.19† 0.005
Stearic acid (18:0) 8.64  0.29 8.22  0.22 7.86  0.20‡ 0.027
Total SFAs 34.14  0.79 32.63  0.61 32.04  0.55‡ 0.037
Palmitoleic acid (16:1) 2.08  0.08 1.85  0.06‡ 1.84  0.05‡ 0.028
Oleic acid (18:1) 29.95  0.41 29.79  0.32 29.60  0.29 NS
Total MUFAs 32.84  0.42 32.41  0.32 32.23  0.29 NS
Linoleic acid (18:2) 10.58  0.69 12.63  0.53‡ 13.25  0.48† 0.003
Linolenic acid (18:3) 1.21  0.10 1.34  0.08 1.34  0.07 NS
Arachidonic acid (20:4) 0.15  0.02 0.17  0.02 0.18  0.01 NS
EPA (20:5) 0.02  0.01 0.03  0.01 0.04  0.01 NS
DHA (22:6) 0.05  0.01 0.07  0.01 0.09  0.012‡ 0.021
Total PUFAs 12.15  0.78 14.40  0.60‡ 15.03  0.54† 0.005
Data are means  SE. *FA intake was adjusted for energy and total fat intake; total fat, carbohydrate, and
protein intakes were adjusted for total energy intake; †P  0.01 vs. GDM; ‡P  0.05 vs. GDM. NS, not
signiﬁcant.
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care.diabetesjournals.org DIABETES CARE, VOLUME 33, NUMBER 9, SEPTEMBER 2010 2053moderate correlations for individual
PUFAs.
In summary, our study suggests that
the absolute concentrations, as opposed
to relative proportions, of fasting serum
FAs were elevated not only in women
with GDM but also in gravidae with less
severe hyperglycemia. In addition, gravi-
dae with impaired GCT, non-GDM, and
especially those who were overweight or
obese have abnormalities in fat metabo-
lism that parallel their hyperglycemia.
The differences are largely dependent on
maternal adiposity. Thus, reducing pre-
gravid weight and altering diet to include
more polyunsaturated fat and less satu-
rated fat might reduce circulating FAs,
decrease insulin resistance and inﬂamma-
tion, and lower future maternal risk of type
2 diabetes and cardiovascular disease.
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